JGC
CYNA

J. Goldman & Co’s CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) CYNA Stock Holding History

J. Goldman & Co’s Portfolio CYNA Stock Details CYNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-58,500
Closed -$980K – 476
2016
Q2 		$980K Sell
58,500
-15,300
-21% -$206K 0.05% 258
2016
Q1 		$878K Sell
73,800
-34,200
-32% -$458K 0.05% 231
2015
Q4 		$1.65M Sell
108,000
-27,000
-20% -$410K 0.17% 149
2015
Q3 		$2.18M Sell
135,000
-148,000
-52% -$2.4M 0.19% 136
2015
Q2 		$4.61M Buy
+283,000
New +$4.64M 0.28% 98

Other funds holding CYNA

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BHMP
Bardin Hill Management Partners New York $80.3M AUM 31.39% 1-Year Est. Return
CC
Coastland Capital Palo Alto, California $1.6B AUM 29.3% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

J. Goldman & Co's CYNA Position: Q3 2016 in Review

J. Goldman & Co sold out of CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) (CYNA) in Q3 2016, closing a stake of 58,500 shares — an estimated $980K sold.

J. Goldman & Co first reported a position in CYNA in Q2 2015 and held it in 5 quarters. The position peaked at $4.61M in Q2 2015. 60 funds tracked by Wall St. Rank hold CYNA as of Q3 2016.

  • J. Goldman & Co reported no remaining CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position as of Q3 2016 after selling out during the quarter.
  • J. Goldman & Co sold 58,500 CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) shares in Q3 2016, an estimated $980K.
  • J. Goldman & Co first reported a position in CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q2 2015 and held it in 5 quarters.
  • J. Goldman & Co's CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position peaked at $4.61M in Q2 2015.
  • 60 funds tracked by Wall St. Rank held CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) as of Q3 2016.

Based on J. Goldman & Co's 13F filing for Q3 2016, filed 14 Nov 2016.